What is Biorelate?
Biorelate specializes in advanced data curation technology tailored for the biopharmaceutical industry. Their core mission is to empower bioinformatics professionals in identifying and validating novel drug targets, elucidating mechanisms of action, and thoroughly exploring target-drug-disease relationships. The company's flagship product, Galactic AI, is a comprehensive knowledge graph designed to connect causal insights derived from a multitude of diverse sources. This platform significantly streamlines the complex research processes inherent in drug development, serving a clientele that ranges from global pharmaceutical leaders such as Pfizer and AstraZeneca to agile, innovative biotech firms. By harnessing Biorelate's technology, clients can accelerate their discovery pipelines and refine decision-making throughout the drug development lifecycle.
How much funding has Biorelate raised?
Biorelate has raised a total of $6.5M across 1 funding round:
Series A
$6.5M
Series A (2022): $6.5M with participation from Triple Point Ventures, YFM Equity Partners, Manchester Technology Fund, and Maven Capital Partners UK
Key Investors in Biorelate
Triple Point Ventures
Triple Point Ventures is a VC firm specializing in early-stage B2B software companies, providing seed and pre-seed investments with a focus on AI, data, and healthcare sectors.
YFM Equity Partners
YFM Equity Partners is a private equity business that supports project development and offers coaching for entrepreneurs, with a focus on UK-based ventures.
Manchester Technology Fund
The Manchester Technology Fund is an early-stage equity fund dedicated to supporting spin-out companies from the University of Manchester across various technologies, including Life Sciences.
What's next for Biorelate?
With the recent major strategic investment, Biorelate is poised for accelerated growth and enhanced market penetration. The enterprise-level funding suggests a transition into a scaling phase, likely focusing on expanding its technological capabilities, broadening its client base, and further solidifying its position as a leader in AI-driven biopharmaceutical data curation. Future developments may include deeper integration of Galactic AI into existing research workflows and the introduction of new analytical modules to address emerging challenges in drug discovery and development. The company's strategic focus on connecting disparate data sources positions it to capitalize on the increasing demand for efficient and accurate insights in life sciences research.
See full Biorelate company page
